Literature DB >> 6122754

[Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

W H Hörl, M Hörl, A Heidland.   

Abstract

Hypertriglyceridaemia is often observed in patients (1) with chronic renal insufficiency, (2) on haemodialysis and (3) after successful renal transplantation. HDL cholesterol is reduced in all three groups of patients and plasma cholesterol is elevated after renal transplantation. In these three patient groups type IV hyperlipoproteinaemia is found most frequently and after renal transplantation there is a relative increase in the incidence of type II hyperlipoproteinaemia. The role of glucagon resistance and carnitine deficiency in the alteration of fat metabolism seen in patients with chronic renal failure and patients on haemodialysis is discussed. Other factors which may influence fat metabolism in uraemia include calcium and vitamin D status as well as beta adrenergic receptor blocking agents and diuretics. Steroid therapy may be one cause of the hypercholesterolaemia and hypertriglyceridaemia seen after renal transplantation. PHLP lipase activity is reduced in all three groups of patients. In nephrotic syndrome, if hypercholesterolaemia occurs, the HDL cholesterol fraction is increased and thus the cardiovascular risk may be lower than in the three patient group mentioned above.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6122754     DOI: 10.1007/bf01721622

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  128 in total

1.  Hypertriglyceridemia in patients with chronic renal insufficiency.

Authors:  E J McCosh; K Solangi; J M Rivers; A Goodman
Journal:  Am J Clin Nutr       Date:  1975-09       Impact factor: 7.045

2.  Negative feedback mechanism of cholesterol synthesis in experimental nephrosis.

Authors:  U DUBACH; L RECANT; E HATCH; M B KOCH
Journal:  Proc Soc Exp Biol Med       Date:  1961-01

Review 3.  Drug therapy: metoprolol.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

4.  Serum lipids in renal insufficiency.

Authors:  C C Heuck; E Ritz; M Liersch; O Mehls
Journal:  Am J Clin Nutr       Date:  1978-09       Impact factor: 7.045

5.  Combined report on regular dialysis and transplantation in Europe, II, 1971.

Authors:  F P Brunner; H J Gurland; H Härlen; K Schärer; F M Parsons
Journal:  Proc Eur Dial Transplant Assoc       Date:  1972

6.  Ischaemic heart-disease as a complication of nephrotic syndrome.

Authors:  G M Berlyne; N P Mallick
Journal:  Lancet       Date:  1969-08-23       Impact factor: 79.321

7.  Lipid metabolism in acute and chronic renal failure.

Authors:  M S Losowsky; D H Kenward
Journal:  J Lab Clin Med       Date:  1968-05

8.  Effect of acetate administration on blood lipids.

Authors:  F K Port; R E Easterling; R V Barnes
Journal:  Am J Clin Nutr       Date:  1978-10       Impact factor: 7.045

9.  Serum lipid and lipoprotein concentrations in chronic uremia.

Authors:  H E Norbeck; L Orö; L A Carlson
Journal:  Acta Med Scand       Date:  1976

10.  Comparison of acetate-1-14C metabolism in uremic and nonuremic dogs.

Authors:  W D Davidson; S J Rorke; L S Guo; R J Morin
Journal:  Am J Clin Nutr       Date:  1978-10       Impact factor: 7.045

View more
  4 in total

1.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

2.  [Fat and renal failure--therapeutic aspects].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-08

Review 3.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01

4.  Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency.

Authors:  R Kirsten; B Heintz; K Nelson; H G Sieberth; G Oremek; J Hasford; U Speck
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.